Overview

LEO 29102 Single and Multiple Dose Study by Dermal Application

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy male subjects. The study is divided into one single dose part followed by a multiple dose part.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma